CIK 1606074
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2020-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 51.63% | 3 |
| Unclassified | 48.37% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | NGM BIOPHARMACEUTICALS INC | Unclassified | 23.39% | |
| 2 | RVMD | Revolution Medicines, Inc. | Health Care | 22.65% |
| 3 | NRIX | Nurix Therapeutics, Inc. | Health Care | 19.24% |
| 4 | RAPT THERAPEUTICS INC | Unclassified | 14.79% | |
| 5 | CONSTELLATION PHARMACEUTICALS INC. | Unclassified | 10.00% | |
| 6 | ORIC | Oric Pharmaceuticals, Inc. | Health Care | 9.73% |
| 7 | GRITSTONE BIO INC | Unclassified | 0.19% |
3/7 names classified · sector 51.6% of weight · industry 51.6% · mkt cap 51.6%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 51.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/4 names) · unclassified 100.0%: , RVMD, NRIX, ORIC. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | NGM BIOPHARMACEUTICALS INC | 18,017,932 | $287M | 23.4% | HOLD |
| 2 | RVMDREVOLUTION MEDICINES INC | 7,977,384 | $278M | 22.7% | HOLD |
| 3 | NRIXNURIX THERAPEUTICS INC | 6,755,881 | $236M | 19.2% | NEW |
| 4 | RAPT THERAPEUTICS INC | 5,630,497 | $181M | 14.8% | TRIM −17% |
| 5 | CONSTELLATION PHARMACEUTICALS INC. | 6,051,376 | $123M | 10.0% | HOLD |
| 6 | ORICORIC PHARMACEUTICALS INC | 4,768,181 | $119M | 9.7% | HOLD |
| 7 | GRITSTONE BIO INC | 869,493 | $2M | 0.2% | TRIM −49% |
Where this firm's principals came from and which firms its alumni went on to found.
